Trial record 1 of 1 for:
FUF15
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Children Aged 6 Months to 9 Years
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00952419 |
Recruitment Status :
Completed
First Posted : August 6, 2009
Results First Posted : July 11, 2011
Last Update Posted : April 14, 2016
|
Sponsor:
Sanofi Pasteur, a Sanofi Company
Information provided by (Responsible Party):
Sanofi ( Sanofi Pasteur, a Sanofi Company )
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Prevention |
Conditions |
Influenza Swine-origin A/H1N1 Influenza |
Interventions |
Biological: Monovalent Subvirion A/H1N1 Influenza vaccine Biological: Normal saline solution (placebo) |
Enrollment | 474 |
Participant Flow
Recruitment Details | Participants were enrolled from 06 August 2009 to 13 August 2009 at 19 US clinical centers. |
Pre-assignment Details | A total of 474 participants who met the inclusion and exclusion criteria were enrolled, vaccinated, and included in data analysis. |
Arm/Group Title | A/H1N1 Vaccine Group 1 | A/H1N1 Vaccine Group 2 | Placebo Group |
---|---|---|---|
![]() |
Participants who received a dose of 7.5 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively. | Participants who received a dose of 15 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively. | Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively. |
Period Title: Overall Study | |||
Started | 215 | 208 | 51 |
Completed | 209 | 198 | 51 |
Not Completed | 6 | 10 | 0 |
Reason Not Completed | |||
Adverse Event | 2 | 0 | 0 |
Protocol Violation | 3 | 7 | 0 |
Withdrawal by Subject | 1 | 3 | 0 |
Baseline Characteristics
Arm/Group Title | A/H1N1 Vaccine Group 1 | A/H1N1 Vaccine Group 2 | Placebo Group | Total | |
---|---|---|---|---|---|
![]() |
Participants who received a dose of 7.5 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively. | Participants who received a dose of 15 μg hemagglutinin intramuscularly on Day 1 and Day 21, respectively. | Participants who received a dose of placebo (saline) intramuscularly on Day 1 and Day 21, respectively. | Total of all reporting groups | |
Overall Number of Baseline Participants | 215 | 208 | 51 | 474 | |
![]() |
[Not Specified]
|
||||
Age, Categorical
Measure Type: Count of Participants Unit of measure: Participants |
|||||
Number Analyzed | 215 participants | 208 participants | 51 participants | 474 participants | |
<=18 years |
215 100.0%
|
208 100.0%
|
51 100.0%
|
474 100.0%
|
|
Between 18 and 65 years |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
>=65 years |
0 0.0%
|
0 0.0%
|
0 0.0%
|
0 0.0%
|
|
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
|||||
Number Analyzed | 215 participants | 208 participants | 51 participants | 474 participants | |
4.1 (2.8) | 4.3 (2.8) | 3.7 (2.7) | 4.2 (2.8) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
|||||
Number Analyzed | 215 participants | 208 participants | 51 participants | 474 participants | |
Female |
111 51.6%
|
99 47.6%
|
24 47.1%
|
234 49.4%
|
|
Male |
104 48.4%
|
109 52.4%
|
27 52.9%
|
240 50.6%
|
|
Region of Enrollment
Measure Type: Number Unit of measure: Participants |
|||||
United States | Number Analyzed | 215 participants | 208 participants | 51 participants | 474 participants |
215 | 208 | 51 | 474 |
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
the PI's rights to discuss or publish trial results after the trial is completed.
Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications
Results Point of Contact
Name/Title: | Medical Director |
Organization: | Sanofi Pasteur Inc. |
EMail: | RegistryContactUs@sanofipasteur.com |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Sanofi ( Sanofi Pasteur, a Sanofi Company ) |
ClinicalTrials.gov Identifier: | NCT00952419 |
Other Study ID Numbers: |
FUF15 UTN: U1111-1111-4713 |
First Submitted: | August 3, 2009 |
First Posted: | August 6, 2009 |
Results First Submitted: | June 8, 2011 |
Results First Posted: | July 11, 2011 |
Last Update Posted: | April 14, 2016 |